Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms

Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly. Ruxolitinib is the first clinically useful targeted therapy in Philadelphia chromosome-negative myeloproliferative neopla...

Descripción completa

Detalles Bibliográficos
Autores principales: Eliaçık, Eylem, Işık, Ayşe, Aksu, Salih, Üner, Ayşegül, Büyükaşık, Yahya, Sayınalp, Nilgün, Göker, Hakan, Özcebe, Osman İ., Haznedaroğlu, İbrahim C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2015
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451485/
https://www.ncbi.nlm.nih.gov/pubmed/26316485
http://dx.doi.org/10.4274/tjh.2013.0265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451485/
https://www.ncbi.nlm.nih.gov/pubmed/26316485
http://dx.doi.org/10.4274/tjh.2013.0265

Ejemplares similares